Pujol, Julien ; Université de Liège > Département de sciences fonctionnelles (DSF) > GIGA-R : Biochimie et biologie moléculaire
Bouillenne, Fabrice ; Université de Liège > Département des sciences de la vie > Centre d'ingénierie des protéines
Farnir, Frédéric ; Université de Liège > Département de productions animales > Biostatistiques et bioinformatique appliquées aux sc. vétér.
Dufrasne, Isabelle ; Université de Liège > Département de productions animales > Nutrition des animaux domestiques
Mainil, Jacques ; Université de Liège > Département des maladies infectieuses et parasitaires (DMI) > Bactériologie et pathologie des maladies bactériennes
Ahonen C.L., Doxsee C.L., McGurran S.M., Riter T.R., Wade W.F., Barth R.J., Vasilakos J.P., Noelle R.J., Kedl R.M. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J. Exp. Med. 2004, 199:775-784.
Arbibe L., Mira J.P., Teusch N., Kline L., Guha M., Mackman N., Godowski P.J., Ulevitch R.J., Knaus U.G. Toll-like receptor 2-mediated NF-kappa B activation requires a Rac1-dependent pathway. Nat. Immunol. 2000, 1:533-540.
Armitage R.J., Fanslow W.C., Strockbine L., Sato T.A., Clifford K.N., Macduff B.M., Anderson D.M., Gimpel S.D., Smith T.D., Maliszewski C.R., Clark E.A., Smith C.A., Grabstein K.H., Cosman D., Spriggs M.K. Molecular and biological characterization of a murine ligand for CD40. Nature 1992, 357:80-82.
Auten M.W., Huang W., Dai G., Ramsay A.J. CD40 ligand enhances immunogenicity of vector-based vaccines in immunocompetent and CD4+ T cell deficient individuals. Vaccine 2012, 30:2768-2777.
Baccam M., Bishop G.A. Membrane-bound CD154, but not CD40-specific antibody, mediates NF-kappaB-independent IL-6 production in B cells. Eur. J. Immunol. 1999, 29:3855-3866.
Banchereau J., de Paoli P., Valle A., Garcia E., Rousset F. Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science 1991, 251:70-72.
Barrett T.B., Shu G., Clark E.A. CD40 signaling activates CD11a/CD18 (LFA-1)-mediated adhesion in B cells. J. Immunol. 1991, 146:1722-1729.
Beland J.L., Adler H., Del-Pan N.C., Kozlow W., Sung J., Fanslow W., Rimm I.J. Recombinant CD40L treatment protects allogeneic murine bone marrow transplant recipients from death caused by herpes simplex virus-1 infection. Blood 1998, 92:4472-4478.
Bennett S.R., Carbone F.R., Karamalis F., Flavell R.A., Miller J.F., Heath W.R. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998, 393:478-480.
Billiau A., Matthys P. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J. Leukoc. Biol. 2001, 70:849-860.
Buddle B.M., Parlane N.A., Wedlock D.N., Heiser A. Overview of vaccination trials for control of tuberculosis in cattle, wildlife and humans. Transbound. Emerg. Dis. 2013, 60:136-146.
Cao J., Wang X., Du Y., Li Y., Wang X., Jiang P. CD40 ligand expressed in adenovirus can improve the immunogenicity of the GP3 and GP5 of porcine reproductive and respiratory syndrome virus in swine. Vaccine 2010, 28:7514-7522.
Diehl L., den Boer A.T., Schoenberger S.P., van der Voort E.I., Schumacher T.N., Melief C.J., Offringa R., Toes R.E. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 1999, 5:774-779.
Fanslow W.C., Srinivasan S., Paxton R., Gibson M.G., Spriggs M.K., Armitage R.J. Structural characteristics of CD40 ligand that determine biological function. Semin. Immunol. 1994, 6:267-278.
French R.R., Chan H.T., Tutt A.L., Glennie M. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med. 1999, 5:548-553.
Gómez C.E., Nájera J.L., Sánchez R., Jiménez V., Esteban M. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens. Vaccine 2009, 27:3165-3174.
Gupta S., Termini J.M., Raffa F.N., Williams C.A., Kornbluth R.S., Stone G.W. Vaccination with a fusion protein that introduces HIV-1 gag antigen into a multitrimer CD40L construct results in enhanced CD8+ T cell responses and protection from viral challenge by vaccinia-gag. J. Virol. 2014, 88:1492-1501.
Gurunathan S., Irvine K.R., Wu C.Y., Cohen J.I., Thomas E., Prussin C., Restifo N.P., Seder R.A. CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. J. Immunol. 1998, 161:4563-4571.
Halasa T., Huijps K., Osteras O., Hogeveen H. Economic effects of bovine mastitis and mastitis management: a review. Vet. Q. 2007, 29:18-31.
Harbury P.B., Zhang T., Kim P.S., Alber T. A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science 1993, 262:1401-1407.
Harcourt J.L., Brown M.P., Anderson L.J., Tripp R.A. CD40 ligand (CD154) improves the durability of respiratory syncytial virus DNA vaccination in BALB/c mice. Vaccine 2003, 21:2964-2979.
Haswell L.E., Glennie M.J., Al-Shamkhani A. Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154. Eur. J. Immunol. 2001, 31:3094-3100.
Hollenbaugh D., Grosmaire L.S., Kullas C.D., Chalupny N.J., Braesch-Andersen S., Noelle R.J., Stamenkovic I., Ledbetter J.A., Aruffo A. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J. 1992, 11:4313-4321.
Jabara H.H., Fu S.M., Geha R.S., Vercelli D. CD40 and IgE: synergism between anti-CD40 monoclonal antibody and interleukin 4 in the induction of IgE synthesis by highly purified human B cells. J. Exp. Med. 1990, 172:1861-1864.
Karmann K., Hughes C.C., Schechner J., Fanslow W.C., Pober J.S. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:4342-4346.
Karpusas M., Hsu Y.M., Wang J.H., Thompson J., Lederman S., Chess L., Thomas D. 2 A crystal structure of an extracellular fragment of human CD40 ligand. Structure 1995, 3:1031-1039.
Lauterbach H., Pätzold J., Kassub R., Bathke B., Brinkmann K., Chaplin P., Suter M., Hochrein H. Genetic adjuvantation of recombinant MVA with CD40L potentiates CD8 T cell mediated immunity. Front. Immunol. 2013, 4:251. 10.3389/fimmu.2013.00251.
Leroux-Roels G. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 2010, 28:C25-C36.
Lim S.Y., Bauermeister A., Kjonaas R.A., Ghosh S.K. Phytol-based novel adjuvants in vaccine formulation: 2, assessment of efficacy in the induction of protective immune responses to lethal bacterial infections in mice. J. Immune Based Ther. Vaccines 2006, 4:5.
Liu J., Yu Q., Stone G.W., Yue F.Y., Ngai N., Jones R.B., Kornbluth R.S., Ostrowski M.A. CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals. Vaccine 2008, 26:4062-4072.
Magalhães P.O., Lopes A.M., Mazzola P.G., Rangel-Yagui C., Penna T.C.V., Pessoa A. Methods of endotoxin removal from biological preparations: a review. J. Pharm. Pharm. Sci. 2007, 10:388-404.
Mazzei G.J., Edgerton M.D., Losberger C., Lecoanet-Henchoz S., Graber P., Durandy A., Gauchat J.F., Bernard A., Allet B., Bonnefoy J.Y. Recombinant soluble trimeric CD40 ligand is biologically active. J. Biol. Chem. 1995, 270:7025-7028.
Middleton J.R. Staphylococcus aureus antigens and challenges in vaccine development. Expert. Rev. Vaccines 2008, 7:805-815.
Morris A.E., Remmele R.L., Klinke R., Macduff B.M., Fanslow W.C., Armitage R.J. Incorporation of an isoleucine zipper motif enhances the biological activity of soluble CD40L (CD154). J. Biol. Chem. 1999, 274:418-423.
O'Shea E.K., Rutkowski R., Kim P.S. Evidence that the leucine zipper is a coiled coil. Science 1989, 243:538-542.
Olsen S.C. Recent developments in livestock and wildlife brucellosis vaccination. Rev. Sci. Tech. 2013, 32:207-217.
Paulie S., Rosén A., Ehlin-Henriksson B., Braesch-Andersen S., Jakobson E., Koho H., Perlmann P. The human B lymphocyte and carcinoma antigen, CDw40, is a phosphoprotein involved in growth signal transduction. J. Immunol. 1989, 142:590-595.
Peter I., Nawrath M., Kamarashev J., Odermatt B., Mezzacasa A., Hemmi S. Immunotherapy for murine K1735 melanoma: combinatorial use of recombinant adenovirus expressing CD40L and other immunomodulators. Cancer Gene Ther. 2002, 9:597-605.
Quezada S.A., Jarvinen L.Z., Lind E.F., Noelle R.J. CD40/CD154 interactions at the interface of tolerance and immunity. Annu. Rev. Immunol. 2004, 22:307-328.
Raaperi K., Orro T., Viltrop A. Epidemiology and control of bovine herpesvirus 1 infection in Europe. Vet. J. 2014, 201:249-256.
Ridge J.P., Di Rosa F., Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998, 393:474-478.
Ridpath J.F. Immunology of BVDV vaccines. Biologicals 2013, 41:14-19.
Rolph M.S., Kaufmann S.H. CD40 signaling converts a minimally immunogenic antigen into a potent vaccine against the intracellular pathogen Listeria monocytogenes. J. Immunol. 2001, 166:5115-5121.
Schoenberger S.P., Toes R.E., van der Voort E.I., Offringa R., Melief C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998, 393:480-483.
Sin J.I., Kim J.J., Zhang D., Weiner D.B. Modulation of cellular responses by plasmid CD40L: CD40L plasmid vectors enhance antigen-specific helper T cell type 1 CD4+ T cell-mediated protective immunity against herpes simplex virus type 2 in vivo. Hum. Gene Ther. 2001, 12:1091-1102.
Stone G.W., Barzee S., Snarsky V., Kee K., Spina C.A., Yu X.F., Kornbluth R.S. Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. J. Virol. 2006, 80:1762-1772.
Thienel U., Loike J., Yellin M.J. CD154 (CD40L) induces human endothelial cell chemokine production and migration of leukocyte subsets. Cell. Immunol. 1999, 198:87-95.
Tripp R.A., Jones L., Anderson L.J., Brown M.P. CD40 ligand (CD154) enhances the Th1 and antibody responses to respiratory syncytial virus in the BALB/c mouse. J. Immunol. 2000, 164:5913-5921.
van Kooten C., Banchereau J. CD40-CD40 ligand. J. Leukoc. Biol. 2000, 67:2-17.
van Mierlo G.J., den Boer A.T., Medema J.P., van der Voort E.I., Fransen M.F., Offringa R., Melief C.J., Toes R.E. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:5561-5566.
Wallemacq H., Bedoret D., Pujol J., Desmet C., Drion P.V., Farnir F., Mainil J., Lekeux P., Bureau F., Fiévez L. CD40 triggering induces strong cytotoxic T lymphocyte responses to heat-killed Staphylococcus aureus immunization in mice: a new vaccine strategy for staphylococcal mastitis. Vaccine 2012, 30:2116-2124.
Wells J.W., Cowled C.J., Farzaneh F., Noble A. Combined triggering of dendritic cell receptors results in synergistic activation and potent cytotoxic immunity. J. Immunol. 2008, 181:3422-3431.
Würtzen P.A., Nissen M.H., Claesson M.H. Maturation of dendritic cells by recombinant human CD40L-trimer leads to a homogeneous cell population with enhanced surface marker expression and increased cytokine production. Scand. J. Immunol. 2001, 53:579-587.
Yang W., Zerbe H., Petzl W., Brunner R., Günther J., Draing C., von Aulock S., Schuberth H.J., Seyfert H.M. Bovine TLR2 and TLR4 properly transduce signals from Staphylococcus aureus and E. coli, but S. aureus fails to both activate NF-kappaB in mammary epithelial cells and to quickly induce TNFalpha and interleukin-8 (CXCL8) expression in the udder. Mol. Immunol. 2008, 45:1385-1397.
Yi Q., Szmania S., Freeman J., Qian J., Rosen N.A., Viswamitra S., Cottler-Fox M., Barlogie B., Tricot G., van Rhee F. Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients. Br. J. Haematol. 2010, 150:554-564.